Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection

被引:0
|
作者
Klim, Sebastian M. [1 ]
Prattes, Juergen [2 ]
Amerstorfer, Florian [1 ]
Niedrist, Tobias [3 ]
Zurl, Christoph [2 ]
Stradner, Martin [4 ]
Dreo, Barbara [4 ]
Glehr, Gunther [5 ]
Leithner, Andreas [1 ]
Glehr, Mathias [1 ]
Reinbacher, Patrick [1 ]
Sadoghi, Patrick [1 ]
Hauer, Georg [1 ]
机构
[1] Med Univ Graz, Dept Orthopaed & Trauma, A-8036 Graz, Austria
[2] Med Univ Graz, Dept Internal Med, Div Infect Dis, A-8036 Graz, Austria
[3] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, A-8036 Graz, Austria
[4] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, A-8036 Graz, Austria
[5] Univ Hosp Regensburg, Dept Surg, D-93053 Regensburg, Germany
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 02期
关键词
suPAR; joint infection; synovia; inflammation; diagnostic biomarker; PLASMA; INFLAMMATION; ARTHRITIS; BIOMARKER; SEPSIS; LEVEL;
D O I
10.3390/antibiotics13020179
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Soluble urokinase plasminogen activator receptors (suPARs) are a biomarker for inflammatory diseases. This study aims to investigate its diagnostic properties regarding periprosthetic joint infections (PJI). This retrospective cohort study included adult patients who underwent joint puncture for suspected PJI. The presence of PJI was determined according to the criteria of the European Bone and Joint Infection Society (EBJIS). Laboratory study analyses included the determination of white blood cells (WBC) in whole blood, C-reactive protein (CRP) in blood plasma, and suPAR in both blood plasma and synovial fluid. Appropriate diagnostic cut-off values were identified utilizing Youden's J, and their diagnostic performance was determined by calculating the positive (PPV) and negative predictive value (NPV) for each marker. Sixty-seven cases were included in the final analysis. Forty-three samples (64%) were identified as periprosthetic joint infection (PJI) and twenty-four specimen (36%) were PJI negative cases. The PPV and NPV were 0.80 and 0.70 for synovial suPAR, 0.86 and 0.55 for CRP, 0.84 and 0.31 for WBC and 1.00 and 0.31 for plasma suPAR. Synovial suPAR showed a solid diagnostic performance in this study and has the potential to be an alternative or complementary biomarker for PJI. Further investigations in larger patient collectives are indicated.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Soluble urokinase plasminogen activator receptor (suPAR) promotes atherosclerosis
    Drueke, Tilman B.
    Massy, Ziad A.
    KIDNEY INTERNATIONAL, 2023, 103 (03) : 451 - 454
  • [2] Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
    Garnaes, Emilie
    Mortensen, Christian
    Hobolth, Lise
    Andersen, Ove
    Nehlin, Jan
    Moller, Soren
    PLOS ONE, 2019, 14 (08):
  • [3] The role of soluble urokinase plasminogen activator receptor (suPAR) in the diagnostics of diabetic foot infection
    Aslan, Sevinc
    Demirdal, Tuna
    Erbak, Huriye
    Aslan, Cem
    INFECTIOUS DISEASES, 2020, 52 (02) : 107 - 113
  • [4] Soluble urokinase plasminogen activator receptor (suPAR) in children with nephrotic syndrome
    Malina, Michal
    Zieg, Jakub
    Rosik, Tomas
    Simankova, Nada
    Vondrak, Karel
    Dusek, Jiri
    Seeman, Tomas
    PEDIATRIC NEPHROLOGY, 2013, 28 (08) : 1591 - 1591
  • [5] SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (SUPAR) LEVELS IN PREGNANCY AND PREECLAMPSIA
    Beko, G.
    Biro, E.
    Toldi, G.
    Stenczer, B.
    Molvarec, A.
    Rigo, J.
    Vasarhelyi, B.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S693 - S693
  • [6] SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (SUPAR) AS A PREDICTOR OF CARDIAC ISCHEMIA
    Feroze, Rafey
    Anderson, Elizabeth
    Hawes, Armani
    Launius, Christopher
    Blakely, Penelope
    Murthy, Venkatesh
    Hayek, Salim
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 206 - 206
  • [7] Urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) serum level in patients with malignant lymphomas
    Hus, I
    Cioch, M
    Jawniak, D
    Manko, J
    Dmoszynska, A
    Chrapko, M
    Hus, M
    BULLETIN OF THE VETERINARY INSTITUTE IN PULAWY, 2002, : 141 - 144
  • [8] Auto-activation of plasminogen in the presence of soluble urokinase plasminogen activator receptor (suPAR).
    An, SSA
    Ngo, E
    Greenfield, RS
    BLOOD, 2000, 96 (11) : 71B - 71B
  • [9] Soluble urokinase-type plasminogen activator receptor (suPAR) as new biomarker of the prosthetic joint infection: Correlation with inflammatory cytokines
    Galliera, Emanuela
    Drago, Lorenzo
    Marazzi, Monica Gioia
    Romano, Carlo
    Vassena, Christian
    Romanelli, Massimiliano M. Corsi
    CLINICA CHIMICA ACTA, 2015, 441 : 23 - 28
  • [10] Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia
    Toldi, Gergely
    Biro, Edina
    Szalay, Balazs
    Stenczer, Balazs
    Molvarec, Attila
    Rigo, Janos, Jr.
    Vasarhelyi, Barna
    Beko, Gabriella
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (11) : 1873 - 1876